OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
LABB58

Genomma Lab Internacional SAB de CV

PharmaceuticalsVerified

Genomma Lab Internacional has a debt-to-equity ratio of 0.69, indicating a moderate level of leverage, and a current ratio of 1.77, suggesting it has sufficient short-term assets to cover its short-term liabilities. The company's liquidity position is assessed as medium, with free cash flow of 630.14 million MXN and operating cash flow of 2.05 billion MXN, but its net cash position is negative after subtracting total debt. The company's profitability is reflected in a return on equity of 14.47% and a return on assets of 6.74%, which are key metrics for evaluating performance in the pharmaceutical industry. These figures suggest that Genomma Lab Internacional is generating a reasonable return on its equity and assets, though the exact comparison to industry medians is not provided in the available data. Geographically, the company's revenue is primarily concentrated in Mexico, as disclosed in its segments, with no significant international revenue streams reported in the available data. This concentration may expose the company to regional economic and regulatory risks. Looking ahead, the company is expected to maintain a stable growth trajectory, with no specific numeric deltas provided for the current or next fiscal year. However, the company's operating income of 3.76 billion MXN and net income of 1.61 billion MXN indicate a solid earnings base. The risk assessment for Genomma Lab Internacional highlights a medium liquidity risk and a low dilution risk. The company's capital structure includes long-term debt of 7.63 billion MXN and cash and equivalents of 2.86 billion MXN, which may affect its financial flexibility. No dilution sources are identified in the available data, and the dilution potential is assessed as low. Recent events and filings do not provide specific details on new product launches, regulatory changes, or strategic partnerships. Analysts have provided a mean price target of 28.10 MXN and a median price target of 29.00 MXN, with a mean recommendation of 2.29, indicating a generally positive outlook.

30-day price · LABB-3.22 (-17.1%)
Low$15.39High$19.48Close$15.65As of25 May, 00:00 UTC
Profile
CompanyGenomma Lab Internacional SAB de CV
TickerLABB.MX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Genomma Lab Internacional SAB de CV is a pharmaceutical company that develops, produces, and distributes a range of pharmaceutical products, primarily in the Mexican market.

Classification. Genomma Lab Internacional is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Genomma Lab Internacional has a debt-to-equity ratio of 0.69, indicating a moderate level of leverage, and a current ratio of 1.77, suggesting it has sufficient short-term assets to cover its short-term liabilities. The company's liquidity position is assessed as medium, with free cash flow of 630.14 million MXN and operating cash flow of 2.05 billion MXN, but its net cash position is negative after subtracting total debt. The company's profitability is reflected in a return on equity of 14.47% and a return on assets of 6.74%, which are key metrics for evaluating performance in the pharmaceutical industry. These figures suggest that Genomma Lab Internacional is generating a reasonable return on its equity and assets, though the exact comparison to industry medians is not provided in the available data. Geographically, the company's revenue is primarily concentrated in Mexico, as disclosed in its segments, with no significant international revenue streams reported in the available data. This concentration may expose the company to regional economic and regulatory risks. Looking ahead, the company is expected to maintain a stable growth trajectory, with no specific numeric deltas provided for the current or next fiscal year. However, the company's operating income of 3.76 billion MXN and net income of 1.61 billion MXN indicate a solid earnings base. The risk assessment for Genomma Lab Internacional highlights a medium liquidity risk and a low dilution risk. The company's capital structure includes long-term debt of 7.63 billion MXN and cash and equivalents of 2.86 billion MXN, which may affect its financial flexibility. No dilution sources are identified in the available data, and the dilution potential is assessed as low. Recent events and filings do not provide specific details on new product launches, regulatory changes, or strategic partnerships. Analysts have provided a mean price target of 28.10 MXN and a median price target of 29.00 MXN, with a mean recommendation of 2.29, indicating a generally positive outlook.
Key takeaways
  • Genomma Lab Internacional has a moderate level of leverage with a debt-to-equity ratio of 0.69.
  • The company's return on equity of 14.47% indicates strong profitability relative to its equity base.
  • The company's liquidity position is assessed as medium, with free cash flow of 630.14 million MXN.
  • The company's revenue is primarily concentrated in Mexico, which may expose it to regional economic and regulatory risks.
  • Analysts have provided a generally positive outlook, with a mean price target of 28.10 MXN and a median price target of 29.00 MXN.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyMXN
Revenue$17.54B
Gross profit$11.02B
Operating income$3.76B
Net income$1.61B
R&D
SG&A
D&A
SBC
Operating cash flow$2.05B
CapEx-$574.6M
Free cash flow$630.1M
Total assets$23.83B
Total liabilities$12.72B
Total equity$11.11B
Cash & equivalents$2.86B
Long-term debt$7.63B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$11.11B
Net cash-$4.77B
Current ratio1.8
Debt/Equity0.7
ROA6.7%
ROE14.5%
Cash conversion1.3%
CapEx/Revenue-3.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricLABBActivity
Op margin21.4%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin9.2%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin62.8%45.5% medp25 31.1% · p75 62.9%above median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-3.3%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity69.0%25.0% medp25 3.8% · p75 63.3%top quartile
Observations
IR observations
Mean price target28.10 MXN
Median price target29.00 MXN
High price target30.00 MXN
Low price target25.50 MXN
Mean recommendation2.29 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count5.00
Hold count2.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate2.16 MXN
Last actual EPS1.65 MXN
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-22 03:20 UTC#fbc078a2
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 09:26 UTCJob: 63a0e5b2